DexCom, Inc.’s Stelo continuous glucose monitor (CGM) became available in the US on 26 August, making it the first such product sold in the country that does not require a prescription. However, Dexcom is likely to face competition soon from its closest rival, Abbott , which is planning to launch its over-the-counter Lingo and Libre Rio CGM.
Dexcom’s Stelo CGM Now Available Without Prescription In US
Dexcom announced the launch of Stelo, the first non-prescription continuous glucose monitoring system to hit the US market, but is likely going to face competition soon from Abbott.
